Anixa Biosciences

Anixa Biosciences (NASDAQ: $ANIX) is focused on the treatment and prevention of cancer.

[Anixa Biosciences @AnixaBio]

Patient who received breast cancer vaccine as part of clinical trial speaks about experience https://t.co/AeWpCo4kQ1

[Anixa Biosciences @AnixaBio]

🎥 #ICYMI: Anixa Biosciences CEO Dr. Amit Kumar appeared on the RedChip Small Stocks, Big Money show on Bloomberg TV.

Discussion highlights:
✔️ Breast cancer vaccine Phase 1 data (immune responses in 74% of participants)
✔️ Progress toward Phase 2
✔️ Ovarian cancer CAR-T program updates

▶️ Watch the interview:
https://t.co/xkoGHOE6y5

#AnixaBiosciences #Biotech #Immunotherapy #CancerResearch #ANIX

[Anixa Biosciences @AnixaBio]

We appreciate the continued coverage from Water Tower Research.

At Anixa Biosciences, we are advancing differentiated immunotherapy programs, including our therapeutic and preventative breast cancer vaccine and lira-cel, our CAR-T therapy for ovarian cancer.

#AnixaBiosciences #Biotech #Immunotherapy #Oncology #CancerResearch #ANIX

[Water Tower Research LLC @WTR_Research]

Dr. Amit Kumar, CEO of @AnixaBio joined us for a fireside chat at the WTR Insights Conference, sharing insights into the company’s strategy, pipeline progress, and long-term growth opportunities. The discussion provides a deeper look at key themes shaping Anixa’s outlook, with additional opportunities to connect with management available through the conference portal.

Make sure to check out the on-demand replay at the link here: https://t.co/3fkpRSRa9u

$ANIX #AnixaBiosciences #Biotech #Immunotherapy #CART #CancerResearch #BreastCancer #OvarianCancer #CancerVaccine #Oncology #ClinicalTrials #BiotechStocks #HealthcareInnovation #LifeSciences #InvestorInsights #WaterTowerResearch

[Anixa Biosciences @AnixaBio]

We’re proud to collaborate with Moffitt Cancer Center on advancing innovative immunotherapy approaches.

Our joint work on CAR-T technology for ovarian cancer reflects a shared commitment to developing differentiated solutions for patients with significant unmet needs.

Appreciate the continued leadership and partnership.

#AnixaBiosciences #MoffittCancerCenter #Biotech #Immunotherapy #CancerResearch

[Moffitt Cancer Center @MoffittNews]

https://t.co/N9pEjvprNn

[Anixa Biosciences @AnixaBio]

We’re pleased to share that Anixa Biosciences will be presenting at the Water Tower Research Insights Conference.

🎤 Dr. Amit Kumar, Chairman & CEO
📅 April 14, 2026
⏰ 12:30 PM ET

Join us as we discuss our clinical programs, including our breast cancer vaccine and CAR-T platform for ovarian cancer.

🔗 Register here:
https://t.co/DFfy1vrkmJ

#AnixaBiosciences #Biotech #Immunotherapy #CancerResearch #ANIX

[Anixa Biosciences @AnixaBio]

We believe Anixa Biosciences is well positioned at the forefront of next-generation oncology innovation.

With our breast cancer vaccine program (in collaboration with Cleveland Clinic) and our CAR-T platform targeting solid tumors, we are advancing differentiated immunotherapy approaches with significant potential.

Momentum in this space continues to build.

#AnixaBiosciences #Biotech #Immunotherapy #CancerResearch #ANIX

[Business-News-Today.com @cricket_fundas]

Why Anixa Biosciences’ Phase 2 breast cancer vaccine push matters more than the manufacturing deal itself https://t.co/gVG7Ou4boT Anixa Biosciences is advancing its breast cancer vaccine toward Phase 2 after positive Phase 1 data. Read what this means for oncology watchers. #AnixaBiosciences #BreastCancerVaccine #TripleNegativeBreastCancer #CancerImmunotherapy #Oncology #Biotech #ClinicalTrials #Cytovance #ClevelandClinic #Phase2Trial @AnixaBio

[Anixa Biosciences @AnixaBio]

Our CEO, Dr. Amit Kumar, joined Smart Money Circle with Adam Sarhan to discuss Anixa’s innovative approach to cancer treatment and prevention.

Watch the full interview: https://t.co/nFJVol4AzV

Thank you @adamsarhan for the conversation.

#Biotech #CancerResearch #Immunotherapy #Oncology #Innovation #Healthcare

[Water Tower Research LLC @WTR_Research]

Check out our latest Healthcare Happenings as we welcome back Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, Inc. (NASDAQ: $ANIX) who explains why 2026 is shaping up to be a pivotal year for the company. Hosted by WTR's Tim Gerdeman & Robert Sassoon. Check out the full episode below!

Podcast Platforms: https://t.co/4Xh9WeH21g
Website: https://t.co/9Ds8aGkSP9

#HealthcareInvesting #Biotech #BiotechStocks $ANIX #CancerResearch #Immunotherapy #BiotechInnovation #HealthcareStocks #LifeSciences #ClinicalDevelopment #PrecisionMedicine #SmallCapBiotech #InvestorInsights #HealthcareInnovation @AnixaBio

[Anixa Biosciences @AnixaBio]

🎙️ New Podcast: Water Tower Research

In this episode of WTR Healthcare Happenings, Anixa Biosciences CEO Dr. Amit Kumar discusses why 2026 may be a pivotal year for Anixa.

🎧 Listen here:
https://t.co/J2ceHI1Abr

The discussion also explores Anixa’s clinical-stage programs, including its ovarian cancer immunotherapy and breast cancer vaccine initiatives.

#AnixaBiosciences #Biotech #CancerResearch #Immunotherapy #ANIX

[Anixa Biosciences @AnixaBio]

🎙️ New podcast: Can we prevent breast cancer?

In this episode, Anixa Biosciences CEO Dr. Amit Kumar discusses the investigational breast cancer vaccine being developed in collaboration with Cleveland Clinic and the clinical research exploring how immunotherapy may help prevent or treat the disease.

▶️ Watch on YouTube:
https://t.co/ulozzdDzC4

🎧 Listen on:
Spotify: https://t.co/RMLPW2FItO
Apple Podcasts: https://t.co/mAEohI5b0e

📺 Media coverage: https://t.co/DmsqC64Whv

#AnixaBiosciences #Biotech #Immunotherapy #CancerResearch #BreastCancer

[Anixa Biosciences @AnixaBio]

An investigational breast cancer vaccine being developed by Anixa Biosciences in collaboration with Cleveland Clinic is featured in new NBC Chicago coverage.

The program is exploring an immunotherapy approach designed to train the immune system to target a protein associated with breast cancer.

🎥 Watch the story:
https://t.co/vclGMmivF3

#AnixaBiosciences #Biotech #CancerResearch #Immunotherapy #ClinicalTrials

[Anixa Biosciences @AnixaBio]

Advancing innovation in the fight against breast cancer 💙

A patient in a clinical trial of our investigational breast cancer vaccine shares her experience—highlighting the potential of this novel immunotherapy approach.

Read more via @foxcarolinanews:
https://t.co/VNSnJQbc0t

#BreastCancer #CancerVaccine #Immunotherapy #ClinicalTrials #Biotech #Oncology

[Anixa Biosciences @AnixaBio]

Encouraging observations from our ovarian cancer CAR-T clinical trial. Multiple patients are living significantly longer than expected and no dose-limiting toxicities have been observed to date. These results support expanded dosing and continued clinical evaluation.

🔗Read the full press release: https://t.co/8Dnh1OJYCe

$ANIX #AnixaBiosciences #CARTTherapy #CancerResearch #ClinicalTrials

[Anixa Biosciences @AnixaBio]

Looking forward to our fireside chat with Robert Sassoon of @WTR_Research at 11:00am ET on Tuesday, February 10. Register to attend here: https://t.co/wXOwv3YWya

[Water Tower Research LLC @WTR_Research]

Please join Robert Sassoon for a fireside chat Anixa Biosciences, Inc. with Chairman & CEO Dr. Amit Kumar, PhD on Tuesday, February 10, 2026, at 11:00 am ET. Register below!

https://t.co/56DKvNTRtc

$ANIX #AnixaBiosciences #FiresideChat #Healthcare #SmallCap #Stocks #Investing @An@AnixaBio

[Anixa Biosciences @AnixaBio]

We're listening to iHeart ♫ @iHeartRadio https://t.co/hKYqolLSa5

[Anixa Biosciences @AnixaBio]

We’re happy to share additional coverage highlighting that the breast cancer vaccine trial, developed with partners including Cleveland Clinic, is advancing into Phase 2 testing after an immune response in over 70% of participants and a favorable safety profile. Phase 2 will include more participants and control comparisons to further evaluate safety and efficacy.

🔗Full article: https://t.co/s6liJy6vSF

$ANIX #AnixaBiosciences #BreastCancerVaccine #Immunotherapy #ClinicalTrials #Biotech

[Ideastream News @Ideastream]

Cleveland Clinic advances promising breast cancer vaccine to second phase trial https://t.co/EK8noAcyfG

[Anixa Biosciences @AnixaBio]

We’re encouraged by worldwide coverage, including by @timesofindia, of the Phase 1 clinical trial results showing our breast cancer vaccine was safe, well-tolerated, and triggered a strong immune response, a hopeful step in the fight against this aggressive disease.

🔗Read the full article: https://t.co/Oom8PBC8QD

$ANIX #AnixaBiosciences #BreastCancer #CancerResearch #Immunotherapy #Biotech

[Anixa Biosciences @AnixaBio]

We’re pleased by news coverage from @NBCNews on the promising Phase 1 clinical trial results for our breast cancer vaccine that generated strong immune responses in Phase 1 — a hopeful step toward prevention and less recurrence for this aggressive cancer subtype.
🔗Read more: https://t.co/XHCflj9RyL
$ANIX #AnixaBiosciences #BreastCancer #Immunotherapy #CancerResearch #Biotech

[Anixa Biosciences @AnixaBio]

📢 We’re encouraged by the promising Phase 1 results from our breast cancer vaccine trial developed in collaboration with Cleveland Clinic — showing the vaccine is safe and triggered an immune response in over 70% of participants.
🔗 Read more: https://t.co/YNKbo97lBH
$ANIX #AnixaBiosciences #BreastCancerVaccine #Immunotherapy #ClinicalTrials #Biotech

[Anixa Biosciences @AnixaBio]

📣 We’re excited to share positive Phase 1 data from our investigational breast cancer vaccine! Final results presented at the 2025 San Antonio Breast Cancer Symposium showed the vaccine met all major primary endpoints, was safe and well tolerated, and elicited protocol-defined immune responses in 74% of participants, supporting advancement into Phase 2 development.

🔗 Full press release: https://t.co/duR95IId7g

$ANIX #AnixaBiosciences #BreastCancerVaccine #BreastCancer #Immunotherapy #ClinicalTrials #Biotech